Improved Pharma Enhances Its In-House Single Crystal Analysis Capabilities

Improved Pharma is taking significant strides forward in the pharmaceutical field by expanding its capabilities for in-house single crystal structure determination. This development comes with the recent acquisition and installation of a state-of-the-art Rigaku XtaLAB Synergy-i diffractometer. This instrument is equipped with cutting-edge technology including a copper X-ray source, a four-circle kappa goniometer, and a pixel array direct photon-counting detector, capable of providing high-quality data from crystals as small as 100 microns.

Single crystal structure determination is regarded as the gold standard in the identification of crystal forms. This method not only enhances our understanding of form purity and density but also provides critical data regarding coformer stoichiometry, unit cell parameters, and unequivocal absolute configurations. Improved Pharma emphasizes the importance of obtaining crystal structures for all forms of interest, with a particular focus on both anhydrous and hydrated forms.

To spearhead this expansion, Improved Pharma has welcomed Jared Smit to its team of expert scientists. With a Bachelor of Science in Chemistry from Wabash College and a Ph.D. in Inorganic Chemistry from Northwestern University, Jared brings a wealth of experience to this role, having previously served as a materials scientist and staff crystallographer at SSCI for over 17 years. His background includes determining hundreds of crystal structures and indexing thousands of X-Ray powder diffraction patterns, all within the context of pharmaceutical solid form development.

Improved Pharma is fundamentally a research, consulting, and information company dedicated to enhancing pharmaceutical methods, formulations, and processes. The services they provide include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting aimed at the development and protection of intellectual property matters. Founded in 2006 by Stephen and Sarah Byrn, the company has built a strong reputation in the industry and continues to drive innovation.

This latest expansion in their facilities is a clear indication of Improved Pharma's commitment to staying at the forefront of pharmaceutical advancements. The enhanced capabilities not only bolster their internal research but also signify their readiness to meet the evolving demands within the pharmaceutical industry. As the company continues to grow, their focus on quality and innovation will play a crucial role in their future endeavors.

In summary, the integration of new crystallographic technology and the addition of expert personnel represents a promising future not just for Improved Pharma, but for the entire pharmaceutical sector, paving the way for better understanding and development of solid forms in drug production.